
Shares of Israel-based drug developer SciSparc SPRC.O rise 36.11% to $3.07 premarket
Co says it has agreed to buy a portfolio of patents and intellectual property for medical devices from Xylo Technologies
The deal includes the "MUSE system," a single-use endoscopic device used in a minimally invasive procedure to treat acid reflux disease, known as GERD
Xylo to get 19.99% of SPRC’s share capital or pre-funded warrants at closing, co says
Co says it plans to replicate Xylo’s China commercialization model in North America, Europe and Latin America
Up to last close, stock down ~68% YTD